DIN 02286386 — TYSABRI 300 MG
TYSABRI is a solution of Natalizumab marketed by BIOGEN CANADA INC. The full Natalizumab monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02286386
- Brand name
- TYSABRI
- Active ingredient
- Natalizumab
- Strength
- 300 MG
- Dosage form
- SOLUTION
- Route
- INTRAVENOUS
- Manufacturer
- BIOGEN CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Selective adhesion molecule inhibitor (monoclonal antibody)
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.